ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Breast Cancer
Carcinoma

Lung Cancer trials near Toronto, ON, CAN:

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (OCELOT)

pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung...

Enrolling
Non-Small Cell Lung Cancer
Drug: Osimertinib First-Line
Drug: Osimertinib Third-Line

Phase 2

Mark Vincent

Toronto, Ontario, Canada and 9 other locations

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Toronto, Canada and 83 other locations

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (P4-PACIFIC)

Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) ...

Begins enrollment in 3 months
Radiation Induced Lung Injury (RILI)
Non-Small Cell Lung Cancer
Other: Placebo
Other: α-Tocopherol

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Toronto, Ontario, Canada and 210 other locations

Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT)

circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer...

Enrolling
Circulating Tumor DNA
Non Small Cell Lung Cancer
Drug: Gemcitabine
Drug: Carboplatin

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decid ...

Enrolling
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Drug: SMS001

Phase 2

ToLymph Inc.

Toronto, Ontario, Canada and 1 other location

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Toronto, Canada and 124 other locations

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) p...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Lung Cancer Patients
Radiation: Non-ablative oligofractionated radiation (NORT)
Drug: Durvalumab

Phase 2

Marc de Perrot

Toronto, Canada

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...

Active, not recruiting
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

Phase 3

Roche
Roche

Brampton, Ontario, Canada and 156 other locations

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small c ...

Enrolling
Stage IV Non-small Cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer
Drug: Crizotinib

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems